Kornimate/medical-research-clean huggingface dataset:
reduction of zygomatic arch in zygomaticomaxillary fractures

Conditions: Zygomatic Arch Reduction

Summary: to compare between ultrasound guided closed reduction and open reduction of zygomatic arch in cases of zygomaticomaxillary fracture. to evaluate the role of intra-operative ultrasound during zygomatic arch reduction. to compare between esthetic appearance, orbital movement, wound healing, scaring, and postoperative ocular complications in both groups.


Eligibility criteria:
inclusion criteria: * patients presenting with zmc fractures that require reduction and fixation * patients between 20 to 50 years old with no gender predilections exclusion criteria: * existence of infection at the fracture line * chronic systemic diseases such as metabolic bone disease, immunocompromised status
an open-label trial of duloxetine for the treatment of irritable bowel syndrome

Conditions: Irritable Bowel Syndrome

Summary: we hypothesize that duloxetine treatment will be associated with improvement in symptoms of ibs, particularly abdominal pain, in individuals without comorbid major depressive disorder. during this 12-week, open-label, outpatient study, male and female subjects between the ages of 18 and 65 years who have been diagnosed with irritable bowel syndrome (ibs) will be treated with open-label duloxetine.

ibs is a chronic gastrointestinal disorder characterized by abdominal pain, altered bowel habits, and abdominal bloating for which no organic cause can be determined. duloxetine has demonstrated efficacy in the treatment of depression as well as in several pain syndromes including diabetic peripheral neuropathy and fibromyalgia. we hypothesize that it will be a safe and efficacious treatment for the symptoms of ibs, in particular abdominal pain. we plan to study 15 male and female subjects between the ages of 18 and 65 years who have had gastrointestinal symptoms at least 2 days/week for greater than six months and who have been diagnosed with ibs by a physician. during the 12-week study, subjects will receive open-label duloxetine titrated up to 60mg/day. subjects will be asked to complete a total of ten study visits during the 12-week study period. all study visits will be conducted at mclean hospital.

Eligibility criteria:
inclusion criteria: * 18-65 years of age * subjects must have been diagnosed with irritable bowel syndrome by a physician * subjects must have had gastrointestinal symptoms for 2 or more days per week for \> 6 months exclusion criteria: * lifetime history of bipolar disorder, psychotic disorder, or obsessive-compulsive disorder * current (within past 6 months) diagnosis of major depressive disorder or substance abuse disorder * active suicidal/homicidal ideation * pregnant women or women of child-bearing potential not using an approved methods of contraception * individuals with an unstable medical condition that in the opinion of the investigator would interfere with the interpretation of symptoms

Keywords: ibs irritable bowel syndrome irritable bowel
intraoperative nitrous oxide and postoperative pain for patients with current opioid treatment

Conditions: Chronic Pain

Summary: peroperative opioids are known to induce n-methyl-d-aspartate dependent enhancement of postoperative hyperalgesia. for patients with current opioid treatment, these phenomena could be exagerated and could produce greater postoperative opioid consumption and higher pain score. since nitrous oxide has anti- n-methyl-d-aspartate properties, the aim of this study was to evaluate, in patients with current opioid treatment, the effects of peroperative nitous oxide on postoperative opioid consumption and pain score, after vertebroplasty.


Eligibility criteria:
inclusion criteria: \> 18 years old current opioid treatment \> 1 month patients scheduled to undergo vertebroplasty with general anesthesia

Keywords: current opioid treatment nitrous oxide chronic pain opioid therapy postoperative hyperalgesia acute opioid tolerance
recruit blood donors via sms during epidemic of covid-19 （repeat trial）

Conditions: Blood Donation

Summary: the fight against the spread of the 2019-ncov epidemic has achieved some success in china, but the epidemic is far from over. a key factor making the epidemic under control in china is the government's call for social distance, which has led to few people going out for donation. as a result, the number of blood donors on the streets has been continuing to decline. the first urgent recruitment of blood donors had been implemented during the period from 30 april to 10 may via emergency recruitment sms . this repeat trial has been designed to further confirm the results from the the first recruitment by comparing which information extraction frameworks would be more sensitive to blood donors in emergency situations.

researches has showed that that the information extraction and processing in emergency was different from the normal situation. to understand what information the blood donors are more sensitive to in an environment that may pose a potential threat to themselves, the first urgent recruitment of blood donors had been implemented during the period from 30 april to 10 . this interventional study is the repeat trail of the first trail. the same with first trail, eligible blood donors in guangzhou blood center has been randomly divided into four groups according to their sociological variables, their interval since last blood donation , their history donation times and the location of their last blood donation. three groups of donors has been randomly selected as interventional groups, and will receive three kindly of emergency blood donor recruitment sms respectively. the placebo group donors will only receive a thank-you sms. one recruitment sms will emphasize what blood services will do to ensure the safety of blood donors during their donation in 2019-ncov epidemic,one will shows information about a loss-based framework, while the third one will show information about a benefit-based framework .

Eligibility criteria:
inclusion criteria: * blood donors whose last turning up were between november 31, 2016 to november 31, 2019 exclusion criteria: * blood donors who were deferral by blood screening result and other situations. blood donors who have indicated that they would not accept urgent recruitment.
ophthalmological disorders in dominant spinal-cerebellar ataxias

Conditions: Spinocerebellar Ataxia

Summary: spinocerebellar ataxias (sca) are rare genetic neurological disorders. the most common forms are sca1, sca2 and sca3. another more recently identified cause of ataxia is sca27b. these are progressive, incapacitating pathologies, with adult onset (generally between 30 and 60 years of age) and progressive involvement. they are characterized by gait instability (ataxia), coordination disorders (dysmetria) and speech disorders (dysarthria). a complex disorder may also be present, with impaired ocular motility, double vision (diplopia) and difficulties with eye movements (ophthalmoplegia). in clinical practice, investigators have observed patients with advanced forms of sca1 or sca3 reporting a progressive decline in visual acuity. other recent scientific observations confirm the possible presence of additional ophthalmological damage to the retina or optic nerve in sca1, sca2 and sca3 pathologies. this study is a cross-sectional study, including subjects with sca1, sca2 and sca3 at different stages of the disease, including the presymptomatic stage, with a complete and systematic study of visual damage. the same study will be applied to subjects with sca27b in order to study the presence or absence of visual impairment, and possibly compare it with those of patients with polyglutamine-expanded sca.


Eligibility criteria:
inclusion criteria: * age between 18 and 80, * presence of pathological expansion in atxn1 (\> or equal to 39 cag), atxn2 (\> or equal to 33 cag) or atxn3 (\> or equal to 45 cag) genes, responsible respectively for sca1, sca2 or sca3 or a pathological expansion (\>250 gaa) in the fgf14 gene responsible for sca27b pathology, * sujet symptomatic (sara greater than or equal to 4) or presymptomatic (sara \< 4). exclusion criteria: * study-specific criteria: * subjects with systemic or ophthalmological disease that could affect the retina, impair fundus examination (severe cataract, severe/decompensated diabetes), or cause visual acuity below 20/40, intraocular pressure \> 20 mmhg, "cup to disc" ratio \> 0. 5, or severe refractive errors * subjects with extremely severe neurological impairment, with a significant impact on the ability to perform most ophthalmological examinations; for example in patients for whom sitting, even with back support and cannot be maintained. the possibility of including subjects with a severe form will be evaluated on a case-by-case basis, according to the opinion of the principal investigator and the ophthalmologist. * general exclusion criteria relating to regulations: * failure to obtain consent (adults, non-emancipated minors, persons not in a position to give consent, research carried out in emergency situations, etc.), * participants who have reached the maximum amount of compensation for their participation inresearch, * non-affiliation with a social security scheme, * persons placed under court protection, * person taking part in research.

Keywords: spinocerebellar ataxias ophtalmology neurology
effect of changes in dialysate bicarbonate on serum calcification propensity and calciprotein particles in hemodialysis patients

Conditions: End Stage Renal Disease

Summary: this is a single-center, prospective, proof-of-priciple, pilot study in 24 end-stage renal disease patients on chronic hemodiaysis.

this single-arm, proof-of-principle study will be conducted at the dialysis facility of the ordensklinikum linz elisabethinen hospital. the dialysate bicarbonate prescription will be decreased from standard of care (usually 35mmol/l) in a stepwise fashion (2 mmol/l per change) to 27 mmol/l and subsequentially increased in a stepwise fashion (2 mmol/l per change) to 37 mmol/l over the course of 6 weeks.

Eligibility criteria:
inclusion criteria: * age ≥18 years * chronic (≥3 months) treatment with hemodialysis or hemodiafiltration * stable clinical condition exclusion criteria: * inability to provide informed consent * dialysis treatment less than thrice weekly * morbid obesity (body mass index \>40 kg/m2) * chronic inflammation (c reactive protein \>10 mg/dl, reference: \<0.5 g/dl) * current immunosuppressive medication, * severe chronic obstructive pulmonary disease (copd stage iii or iv) * history of severe hypercapnia or hypoxemia * overt congestive heart failure * history of severe hypokalemia (\ 6.5 mmol/l) within 3 months prior to study inclusion.
effects of clinical music improvisation on resiliency in adults undergoing infusion therapy

Conditions: Anxiety

Summary: this study will investigate the impact of music therapy on newly diagnosed patients with cancer undergoing chemotherapy. measurements used at baseline, middle and end of first cycle will be the resiliency scale (wagnild and young 1993); the hads scale (hospital anxiety depression scale, zigmond and snaith 1983 )and and the cas scale for pain (color analysis scale).

the purpose of this research study is to examine clinical music therapy's impact on the resiliency of adults undergoing infusion therapy. this research study is being undertaken to learn about how creative music therapy modalities can affect the infusion therapy process. infusion therapy often includes side effects which impact quality of life. symptoms include pain, nausea and anxiety. for newly diagnosed patients anxiety accompanies adjustment to scheduling treatments and side effects. typically patients receiving infusion therapy have no alternative focus for their mind and or body aside from the infusion itself. since the relationship between pain and anxiety is inter-related, altering one modality through a live music intervention may modify the impact of the other modality thus shifting the cycle and overall impact of pain and anxiety providing relief which leads to self soothing control measures. the current research will enroll patients newly diagnosed with either lung, breast, or gastrointestinal cancer that are treated in the infusion suite of slrhc. 100 patients will be randomly assigned to three groups: clinical instrumental improvisation, clinical vocal improvisation or control. all enrolled participants will complete a survey which indicates their music preference, resiliency test , the hospital anxiety and depression scale (hads), visual analogue scale (vas), and body pain scale - color analysis scale (cas).

Eligibility criteria:
inclusion criteria: * 18 and older * diagnosed with breast cancer, lung cancer, or gastro-intestinal cancer exclusion criteria: * under 18 * past cancer(s)
timing for bone marrow mononuclear cells after acute myocardial infarction

Conditions: Myocardial Infarction

Summary: most studies on intracoronary bone marrow mononuclear cell (bmc) transplantation for acute myocardial infarction (ami) involve treatment 3-7 days after primary percutaneous coronary intervention (pci); however, the optimal timing is unknown. the present study assessed the therapeutic effect at different times after st-elevation myocardial infarction (stemi).

on the basis of experimental studies that bone marrow mononuclear cells (bmcs) transfer in the injured tissue can promote regional myocardial perfusion and improved cardiac function, several clinical trials have shown that intracoronary bone marrow mononuclear cell (bmc) transplantation in acute myocardial infarction (ami) patients several days after myocardial reperfusion is safe and may enhance the improvement of left ventricular ejection fraction (lvef). the timing of bmc administration, baseline lvef, dosage of bmc and other factors has been linked to improvement in lvef after bmc transplantation. in our previous work, we gave bmcs within 24 hours after emergency percutaneous coronary intervention (pci) and found that it was safe and effective . in addition, there are another report about longer time from symptom onset to bmc infusion (2-4 weeks), which also appeared effective . the timing of intracoronary stem cell administration may have a critical effect on cell engraftment and may be responsible for the various biological and functional responses to therapy. however, few studies have directly addressed the optimal timing of cell injections. therefore, in this prospective randomized study, bmcs were given at different times (within 24 hours, 3 to 7 days, or 7 to 30 days after reperfusion) to investigate whether the timing of therapy affects the therapeutic response of ami patients.

Eligibility criteria:
inclusion criteria: * a history of first acute st-elevation myocardial infarction * treatment with successful pci two to twelve hours after symptom onset * lvef less than 50% on angiography immediately after emergency pci or rescue pci exclusion criteria: * previous q-wave myocardial infarction * cardiogenic shock * severe coexisting conditions such as acute and chronic heart failure, malignant * arrhythmia, renal failure and severe bleeding that interfered with the ability of the * patient to comply with the protocol

Keywords: cell therapy bmc timing
detectfog : detection of gait freezing episodes in parkinsonian patients using inertial measurement units

Conditions: Parkinson Disease

Summary: parkinson's disease is the second most common neurodegenerative disease in the world. one of these manifestations is the freezing of gait (fog) which affects 50 to 80% of parkinsonian patients. it is defined as a brief and episodic absence or marked reduction in the forward progression of the feet despite the intention to walk. fog is one of the most disabling symptoms causing a greater risk of falling and a loss of autonomy for these patients. this symptom is little or not dopamine-sensitive and little improved by surgery (deep brain stimulation). although this symptom is common and debilitating, it is difficult to assess clinically. the objective assessment of the presence and severity of fog episodes can be done with tests such as the new-freezing of gait questionnaire (n-fogq) with however limitations. indeed, this filmed examination is scored a posteriori and the accumulation of the administration times which makes it difficult to use in routine clinical practice. to overcome these limitations, the use of a diary completed by the patient himself is a simple alternative to assess this symptom, but studies show that patients abandon this practice in the long term and that it is not used by patients with cognitive impairment. recent advances in miniaturization have made it possible to create light and compact sensors to assess these events objectively. inertial measurement units have been widely used in the literature to detect fog episodes. the choice of the detection algorithms are a major issue in the scientific community. to date, due to the heterogeneity of the protocols, no method is currently required as a reference. the objective is to evaluate the accuracy of a new algorithm to detect the number of fog episodes in parkinsonian patients. this evaluation will be done on the freeze-inducing walking path.


Eligibility criteria:
inclusion criteria: * patient over 18 years old * with parkinson's disease according to the united kingdom brain bank criteria * presenting episodes of freezing of gait assessed on the movement disorder society-unified parkinson's disease rating scale (mds-updrs ii - question 13 with a score between 1 and 3 in order to have a patient walking without technical assistance) produced by the neurologist * able to walk 30 meters independently * affiliated to a social security scheme or beneficiary of such a scheme * having signed a free and informed consent in writing exclusion criteria: * montreal cognitive assessment (moca) \< 20/30 * other neurological or orthopedic history that interferes with walking * pregnant, parturient or breastfeeding women * adults subject to legal protection (safeguard of justice, curatorship, guardianship), persons deprived of liberty * persons undergoing psychiatric care, persons admitted to a health or social establishment for purposes other than research * minors * persons unable to express their consent * simultaneous participation in another research related to balance and/or walking

Keywords: freezing of gait
the role of probiotics in improving quality of life in women with functional constipation

Conditions: Constipation - Functional

Summary: this study aimed to investigate the relationship between administration of probiotics and improvement in quality of life in women with functional constipation.


Eligibility criteria:
inclusion criteria: * being declared healthy based on initial examination and the structured interview questionnaire (siq) * having the symptoms and signs of functional constipation refer to rome iv * able to communicate well * able to consume 1 bottle of fermented milk each day for three weeks * not using antibiotic no later than one week before supplementation exclusion criteria: * diagnosed with functional bowel disorder * using anesthesia at least 4 weeks before treatment * having a serious pathological disorder (carcinoma) * during healing phase of acute gastrointestinal disorders at least 4 weeks before treatment * having severe heart disease * taking chronic medications such as antidepressants or analgesics

Keywords: constipation quality of life probiotic pac-qol
study comparing ct scan and stress test in diagnosing coronary artery disease in patients hospitalized for chest pain

Conditions: Coronary Artery Disease; Angina Pectoris; Unstable Angina; Acute Coronary Syndrome

Summary: the purpose of this study is to determine whether coronary artery ct scanning or nuclear stress testing is better at diagnosing chest pain patients with coronary artery disease to select appropriate candidates for coronary catheterization and re-vascularization.


Eligibility criteria:
inclusion criteria: * patient admitted for chest pain or pressure * patient at intermediate short term risk of mi or death (aha/acc guidelines) exclusion criteria: * prior diagnosis of coronary artery disease * evidence of ongoing myocardial infarction (and other high risk criteria per aha/acc guidelines) * contraindications to ekg-gated ct scanning with iodinated intravenous contrast under beta-blockade * pregnancy * presence of an implanted pacemaker or defibrillator * stress myocardial perfusion imaging, coronary cta or coronary catheterization within the last 6 months

Keywords: stress myocardial perfusion imaging coronary computed tomography angiography
effects of exogenous ketosis on renal function, renal perfusion, and sodium excretory capacity in healthy subjects

Conditions: Ketosis; Ketonemia

Summary: this is a randomized, placebo-controlled, double-blinded crossover design. fifteen healthy subjects will be randomized to receive either ketone bodies (ke4) or placebo delivered by ketoneaid. after a period of 5-days treatment, effect variables will be measured (experiment day 1). after a washout period of 14 days, the subjects are crossed over to a similar treatment period with the other treatment. the study is terminated by measuring effect variables after the second treatment period (experiment day 2).

background: renewed interest in ketone bodies has emerged, partly driven by the recent success of selective sodium glucose co transporter 2 (sglt-2) inhibition in preventing cardiovascular deaths in patients with diabetes mellitus (dm) and chronic kidney disease (ckd). effects of ketosis are of importance in order to understand the beneficial effects of sglt-2 inhibitors and to account for the full therapeutic potential of this treatment. hypothesis: ketosis increases renal blood flow and glomerular filtration rate (gfr). methods: it is a randomized, placebo-controlled double-blinded cross over study. fifteen healthy subjects will be randomized to receive either ketone bodies (ke4) or for 5 days. after a wash out period of at least 14 days, the subjects are crossed over to receive the other treatment. after each treatment period effect variables will be measured including technetium(tc)99m - diethylenetriamine pentaacetate (dtpa) clearance and water based positron emission tomography computed tomography (pet/ct) perspectives: the study has the potential to provide information regarding the therapeutic potential of treatment with ketone bodies and understanding of conditions characterized by ketosis, such as sglt2-inhibitor treatment.

Eligibility criteria:
inclusion criteria: * bmi \< 30 kg/m2 * safe contraception if women in childbearing age * normal biochemical screening exclusion criteria: * pregnancy or breast feeding * major heart-, liver-, kidney-, lung-, neurological- or endocrine disease * daily use of prescription drugs (expect for contraceptives) * alcohol or drug abuse * periodic fasting * routinely intake of ketogenic diet

Keywords: kidney circulation kidney physiology kidney function glomerular filtration rate